<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="cts70208" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Sci</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2996</journal-id><journal-id journal-id-type="pmc-domain">cts</journal-id><journal-id journal-id-type="publisher-id">CTS</journal-id><journal-title-group><journal-title>Clinical and Translational Science</journal-title></journal-title-group><issn pub-type="ppub">1752-8054</issn><issn pub-type="epub">1752-8062</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11962518</article-id><article-id pub-id-type="pmcid-ver">PMC11962518.1</article-id><article-id pub-id-type="pmcaid">11962518</article-id><article-id pub-id-type="pmcaiid">11962518</article-id><article-id pub-id-type="pmid">40171834</article-id><article-id pub-id-type="doi">10.1111/cts.70208</article-id><article-id pub-id-type="publisher-id">CTS70208</article-id><article-id pub-id-type="other">CTS-2024-0274-T</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>New Function for Safety Signal Monitoring in <styled-content style="fixed-case" toggle="no">MID</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">NET<sup>&#174;</sup>
</styled-content>: The Case of an Anti&#8208;<styled-content style="fixed-case" toggle="no">COVID</styled-content>&#8208;19 Drug</article-title></title-group><contrib-group><contrib id="cts70208-cr-0001" contrib-type="author"><name name-style="western"><surname>Okada</surname><given-names initials="Y">Yusuke</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3559-4350</contrib-id><xref rid="cts70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70208-cr-0002" contrib-type="author"><name name-style="western"><surname>Ando</surname><given-names initials="T">Takashi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0654-5656</contrib-id><xref rid="cts70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70208-cr-0003" contrib-type="author"><name name-style="western"><surname>Takahashi</surname><given-names initials="F">Fumitaka</given-names></name><xref rid="cts70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70208-cr-0004" contrib-type="author"><name name-style="western"><surname>Watanabe</surname><given-names initials="K">Kenichi</given-names></name><xref rid="cts70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70208-cr-0005" contrib-type="author"><name name-style="western"><surname>Kajiyama</surname><given-names initials="K">Kazuhiro</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0570-2792</contrib-id><xref rid="cts70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70208-cr-0006" contrib-type="author"><name name-style="western"><surname>Hasegawa</surname><given-names initials="T">Tomoaki</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8602-8295</contrib-id><xref rid="cts70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70208-cr-0007" contrib-type="author"><name name-style="western"><surname>Inomata</surname><given-names initials="S">Satomi</given-names></name><xref rid="cts70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70208-cr-0008" contrib-type="author"><name name-style="western"><surname>Kinoshita</surname><given-names initials="Y">Yuki</given-names></name><xref rid="cts70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70208-cr-0009" contrib-type="author"><name name-style="western"><surname>Watanabe</surname><given-names initials="S">Shinya</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-5424-1445</contrib-id><xref rid="cts70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70208-cr-0010" contrib-type="author" corresp="yes"><name name-style="western"><surname>Uyama</surname><given-names initials="Y">Yoshiaki</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0430-9887</contrib-id><xref rid="cts70208-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>uyama-yoshiaki@pmda.go.jp</email></address></contrib></contrib-group><aff id="cts70208-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Office of Medical Informatics and Epidemiology</named-content>
<institution>Pharmaceuticals and Medical Devices Agency</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Yoshiaki Uyama (<email>uyama-yoshiaki@pmda.go.jp</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>18</volume><issue seq="221">4</issue><issue-id pub-id-type="pmc-issue-id">485211</issue-id><issue-id pub-id-type="doi">10.1111/cts.v18.4</issue-id><elocation-id>e70208</elocation-id><history><date date-type="rev-recd"><day>02</day><month>3</month><year>2025</year></date><date date-type="received"><day>21</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-26 13:25:14.117"><day>26</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Clinical and Translational Science</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CTS-18-e70208.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CTS-18-e70208.pdf"/><abstract><title>ABSTRACT</title><p>Real&#8208;world data play a key role in monitoring drug safety at the post&#8208;marketing stage. However, challenges on how to rapidly and continuously obtain analytical results of many outcomes for drug safety signal monitoring still remain. We aimed to establish a rapid and continuous monitoring tool for drug safety assessment based on real&#8208;world data in Japan. An automated process for a new&#8208;user cohort design with customizable analytical conditions was developed. The customizable analytical conditions include exposure and control drugs, 46 outcomes related to liver and kidney functions, blood tests, biomarkers, and time period of interest. Statistical analyses were performed to evaluate the outcome status (present/absent) and calculate the adjusted hazard ratio, with a 95% confidence interval of exposure to control. We monitored the safety signals of an anti&#8208;COVID&#8208;19 drug (combination of tixagevimab and cilgavimab) and compared them with those of two controls (peramivir and the combination of casirivimab and imdevimab) to examine the practical utility of this new tool. Our study provided helpful information (e.g., new safety signals) on many outcomes at multiple time points, which could enhance the understanding of drug safety profiles soon after approval. Our function can be used to rapidly and continuously monitor drug safety signals and contribute to strengthening drug safety monitoring in Japan.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cts70208-kwd-0001">medical information database</kwd><kwd id="cts70208-kwd-0002">post&#8208;marketing drug safety</kwd><kwd id="cts70208-kwd-0003">real&#8208;word evidence</kwd><kwd id="cts70208-kwd-0004">safety signal monitoring</kwd></kwd-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="11"/><word-count count="6600"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.5 mode:remove_FC converted:25.04.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cts70208-ntgp-0001"><fn fn-type="funding" id="cts70208-note-0001"><p>
<bold>Funding:</bold> All authors are employees of the PMDA and have received no specific funding for this work.</p></fn><fn fn-type="equal" id="cts70208-note-0002"><p>Yusuke Okada and Takashi Ando contributed equally to this work.</p></fn></fn-group></notes></front><body id="cts70208-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="cts70208-blkfxd-0001" orientation="portrait"><caption><title>Summary</title></caption><p>
<list list-type="bullet" id="cts70208-list-0001"><list-item id="cts70208-li-0001"><p>What is the current knowledge on this topic?
<list list-type="simple" id="cts70208-list-0002"><list-item id="cts70208-li-0002"><label>&#9675;</label><p>Although real&#8208;world data play a key role in monitoring drug safety at the post&#8208;marketing stage, challenges remain on rapid and continuous safety signal monitoring of a drug for regulatory assessment in Japan.</p></list-item></list>
</p></list-item><list-item id="cts70208-li-0003"><p>What question did this study address?
<list list-type="simple" id="cts70208-list-0003"><list-item id="cts70208-li-0004"><label>&#9675;</label><p>How analytical results of many outcomes can be simultaneously provided in a rapid and continuous manner for drug safety signal monitoring.</p></list-item></list>
</p></list-item><list-item id="cts70208-li-0005"><p>What does this study add to our knowledge?
<list list-type="simple" id="cts70208-list-0004"><list-item id="cts70208-li-0006"><label>&#9675;</label><p>The newly created function with an automatic process was incorporated into MID&#8208;NET<sup>&#174;</sup> in Japan. The practical use of this function to monitor the safety signals of an anti&#8208;COVID&#8208;19 drug, a combination product of tixagevimab and cilgavimab, provided useful information for better safety signal monitoring.</p></list-item></list>
</p></list-item><list-item id="cts70208-li-0007"><p>How might this change clinical pharmacology or translational science?
<list list-type="simple" id="cts70208-list-0005"><list-item id="cts70208-li-0008"><label>&#9675;</label><p>The new function will be used as a tool for rapid and continuous monitoring of drug safety signals on a large number of outcomes from an early post&#8208;marketing stage and can strengthen the system for drug safety assessment in Japan.</p></list-item></list>
</p></list-item></list>
</p></boxed-text>
</p><sec id="cts70208-sec-0004"><label>1</label><title>Introduction</title><p>Signal detection has traditionally relied on spontaneous adverse drug reaction reports, but such reports have several significant limitations, including underreporting and reporting bias due to their voluntary nature [<xref rid="cts70208-bib-0001" ref-type="bibr">1</xref>, <xref rid="cts70208-bib-0002" ref-type="bibr">2</xref>, <xref rid="cts70208-bib-0003" ref-type="bibr">3</xref>]. To improve post&#8208;marketing drug safety assessment, health information databases are increasingly used for signal detection and to assess the specific risks of a drug [<xref rid="cts70208-bib-0004" ref-type="bibr">4</xref>, <xref rid="cts70208-bib-0005" ref-type="bibr">5</xref>]. However, challenges remain in the full use of electronic health records (EHRs) for signal detection [<xref rid="cts70208-bib-0005" ref-type="bibr">5</xref>].</p><p>The Pharmaceuticals and Medical Devices Agency (PMDA) of Japan has utilized MID&#8208;NET<sup>&#174;</sup> as a source of real&#8208;world data (RWD) for post&#8208;marketing drug safety assessment [<xref rid="cts70208-bib-0006" ref-type="bibr">6</xref>, <xref rid="cts70208-bib-0007" ref-type="bibr">7</xref>, <xref rid="cts70208-bib-0008" ref-type="bibr">8</xref>, <xref rid="cts70208-bib-0009" ref-type="bibr">9</xref>, <xref rid="cts70208-bib-0010" ref-type="bibr">10</xref>, <xref rid="cts70208-bib-0011" ref-type="bibr">11</xref>, <xref rid="cts70208-bib-0012" ref-type="bibr">12</xref>, <xref rid="cts70208-bib-0013" ref-type="bibr">13</xref>, <xref rid="cts70208-bib-0014" ref-type="bibr">14</xref>]. It stores EHRs, administrative claims data, and diagnosis/procedure combination data for over 6&#8201;million patients (as of December 2022) from 10 healthcare organizations, including 23 university hospitals and regional core hospitals. One of the unique characteristics of MID&#8208;NET<sup>&#174;</sup> is that many laboratory test results are available for immediate analysis (i.e., updated every week). Our experience with MID&#8208;NET<sup>&#174;</sup> has shown that sequential analysis of outcomes based on laboratory test results can be utilized to continuously monitor drug safety signals [<xref rid="cts70208-bib-0015" ref-type="bibr">15</xref>]. The use of EHR data to analyze many outcomes efficiently has not been well established for routine regulatory assessment in Japan, while such methods have been reported in the United States and EU [<xref rid="cts70208-bib-0004" ref-type="bibr">4</xref>].</p><p>To address this situation, the PMDA recently created a new process that can simultaneously, rapidly, and continuously monitor drug safety signals on many outcomes using EHR data in MID&#8208;NET<sup>&#174;</sup> [<xref rid="cts70208-bib-0016" ref-type="bibr">16</xref>]. The present study describes that function, its practical utility, and the remaining challenges identified through a real use case. We selected a combination product of tixagevimab and cilgavimab (tix/cil) as the case because it was approved under the expedited pathway for the public emergency process in Japan for the prevention and treatment of coronavirus disease 2019 (COVID&#8208;19) in August 2022 [<xref rid="cts70208-bib-0017" ref-type="bibr">17</xref>]. This new function was developed during that time frame, and the rapid accumulation of safety information for the target product at an early stage after approval was essential to facilitate its proper use in clinical practice.</p></sec><sec sec-type="methods" id="cts70208-sec-0005"><label>2</label><title>Methods</title><sec id="cts70208-sec-0006"><label>2.1</label><title>Overview of the Newly Created Function for Safety Signal Monitoring of a Drug in <styled-content style="fixed-case" toggle="no">MID</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">NET<sup>&#174;</sup>
</styled-content>
</title><p>The newly created function has an automated process for data analysis such that the analytical results can be rapidly obtained from MID&#8208;NET<sup>&#174;</sup>,&#160;as shown in Figure&#160;<xref rid="cts70208-fig-0001" ref-type="fig">1</xref>.</p><fig position="float" fig-type="FIGURE" id="cts70208-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Process of the newly created function for safety signal monitoring of a drug in MID&#8208;NET<sup>&#174;</sup>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CTS-18-e70208-g002.jpg"/></fig><p>A researcher (a user of the MID&#8208;NET<sup>&#174;</sup>) submits a study request to the MID&#8208;NET<sup>&#174;</sup> management office after considering the analytical conditions. The automated process begins with data extraction, followed by data processing and statistical analyses. After completing this automated process, the report file containing the analytical results is sent to the researcher in a standardized format, in which the researcher can quickly check the analytical results for interpretation. The programs for this function were developed in C# (Microsoft, Redmond, WA, USA), Powershell 5.1 (Microsoft, Redmond, WA, USA), and SAS 9.4 (SAS Institute, Cary, NC, USA). The executable files were run on &#8220;.NET Framework 4.5&#8221; (Microsoft, Redmond, WA, USA) and PowerShell 7.2 (Microsoft, Redmond, WA, USA) for data extraction and processing and on SAS 9.4 (SAS Institute, Cary, NC, USA) for statistical analyses.</p><p>For the automated process, the study was programmed as a new&#8208;user cohort design with customizable analytical conditions and outcomes. More specifically, a researcher can determine the data period (a given day: start and end dates), target drugs (exposure and control), two look&#8208;back periods (a given day: one is for the inclusion criteria [look&#8208;back period 1] and the other is for baseline laboratory test results [look&#8208;back period 2]), start date of the follow&#8208;up period (<italic toggle="yes">t</italic>
<sub>0</sub> or the next day of <italic toggle="yes">t</italic>
<sub>0</sub>), and a gap/grace period (a given day). The date of the first prescription of the target drug for each patient was set as <italic toggle="yes">t</italic>
<sub>0</sub>. The patients meeting both of the following criteria were included: (1) prescriptions for researcher&#8208;specified drugs (exposure or control) during the data period set by the researcher, and (2) the first medical record date during the data period was at least before the researcher&#8208;specified look&#8208;back period (look&#8208;back period 1: a given day before <italic toggle="yes">t</italic>
<sub>0</sub> to <italic toggle="yes">t</italic>
<sub>0</sub>). The following patients were excluded from the analysis: (1) prescribed both target drugs (exposure and control) at <italic toggle="yes">t</italic>
<sub>0</sub> and (2) <italic toggle="yes">t</italic>
<sub>0</sub> was the last medical record date (only applied when the follow&#8208;up period was started on the next day of <italic toggle="yes">t</italic>
<sub>0</sub>). The study's follow&#8208;up period started at the researcher&#8208;specified timing (<italic toggle="yes">t</italic>
<sub>0</sub> or the next day of <italic toggle="yes">t</italic>
<sub>0</sub>). It ended on the earliest day among the following dates: (1) end date of the prescription period, (2) date of outcome occurrence, (3) start date of the other target drug prescription that differs from <italic toggle="yes">t</italic>
<sub>0</sub>, or (4) date of the last medical record during the data period. The prescription period encompassed the start date (<italic toggle="yes">t</italic>
<sub>0</sub>) and duration of the prescription with researcher&#8208;specified gap and grace periods.</p></sec><sec id="cts70208-sec-0007"><label>2.2</label><title>Available Outcomes in the Function</title><p>As listed in Table&#160;<xref rid="cts70208-tbl-0001" ref-type="table">1</xref>, 46 outcomes were available in the function. Any patient who met the criteria for each outcome during the follow&#8208;up period was identified as a case. The upper and lower limits of the normal range of the laboratory test results were set based on the standard reference intervals established by the Japanese Committee for Clinical Laboratory Standards (see Table&#160;<xref rid="cts70208-supitem-0001" ref-type="supplementary-material">S1</xref> for the actual values set in this function). The estimated glomerular filtration rate (eGFR), neutrophil, eosinophil, and lymphocyte counts, and calcium level were calculated using a commonly used formula in Japan (see Table&#160;<xref rid="cts70208-supitem-0001" ref-type="supplementary-material">S2</xref> for more details).</p><table-wrap position="float" id="cts70208-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Target outcomes in the MID&#8208;NET<sup>&#174;</sup> safety monitoring system.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Outcome No.</th><th align="center" valign="bottom" rowspan="1" colspan="1">Target function of outcome</th><th align="center" valign="bottom" rowspan="1" colspan="1">Outcome name</th><th align="center" valign="bottom" rowspan="1" colspan="1">Outcome definition</th><th align="center" valign="bottom" rowspan="1" colspan="1">Remarks</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" rowspan="13" valign="top" colspan="1">Liver function</td><td align="center" valign="top" rowspan="1" colspan="1">Increased AST (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">AST &gt;&#8201;3&#8201;&#215;&#8201;ULN</td><td align="center" rowspan="4" valign="top" colspan="1">Equivalent to CTCAE v5.0 Grade 2 or higher (if baseline is within reference interval)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">Increased ALT (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">ALT &gt;&#8201;3&#8201;&#215;&#8201;ULN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">Increased ALP (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">ALP &gt;&#8201;2.5&#8201;&#215;&#8201;ULN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">Increased t&#8208;bilirubin (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">T&#8208;bilirubin &gt;&#8201;1.5&#8201;&#215;&#8201;ULN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">Increased AST (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">AST &gt;&#8201;5&#8201;&#215;&#8201;ULN</td><td align="center" rowspan="4" valign="top" colspan="1">Equivalent to CTCAE v5.0 Grade 3 or higher (if baseline is within reference interval)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">Increased ALT (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">ALT &gt;&#8201;5&#8201;&#215;&#8201;ULN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">Increased ALP (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">ALP &gt;&#8201;5&#8201;&#215;&#8201;ULN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">Increased t&#8208;bilirubin (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">T&#8208;bilirubin &gt;&#8201;3&#8201;&#215;&#8201;ULN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">Increased (AST or ALT) and t&#8208;bilirubin</td><td align="center" valign="top" rowspan="1" colspan="1">The following conditions are fulfilled on the same day.
<list list-type="bullet" id="cts70208-list-0006"><list-item id="cts70208-li-0009"><p>AST&#8201;&gt;&#8201;3&#8201;&#215;&#8201;ULN or ALT &gt;&#8201;3&#8201;&#215;&#8201;ULN</p></list-item><list-item id="cts70208-li-0010"><p>T&#8208;bilirubin &gt;&#8201;2&#8201;&#215;&#8201;ULN</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">Set with reference to Hy's Law definition in the FDA guidance<xref rid="cts70208-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">Increased AST and ALT (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">The following conditions are fulfilled on the same day.
<list list-type="bullet" id="cts70208-list-0007"><list-item id="cts70208-li-0011"><p>AST &gt;&#8201;3&#8201;&#215;&#8201;ULN</p></list-item><list-item id="cts70208-li-0012"><p>ALT &gt;&#8201;3&#8201;&#215;&#8201;ULN</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">Combination of the outcome Nos. 1 and 2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">Increased AST and ALT (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">The following conditions are fulfilled on the same day.
<list list-type="bullet" id="cts70208-list-0008"><list-item id="cts70208-li-0013"><p>AST &gt;&#8201;5&#8201;&#215;&#8201;ULN</p></list-item><list-item id="cts70208-li-0014"><p>ALT &gt;&#8201;5&#8201;&#215;&#8201;ULN</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">Combination of the outcome Nos. 5 and 6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">Increased ALP, t&#8208;bilirubin and &#947;&#8208;GTP (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">The following conditions are fulfilled on the same day.
<list list-type="bullet" id="cts70208-list-0009"><list-item id="cts70208-li-0015"><p>ALP &gt;&#8201;2.5&#8201;&#215;&#8201;ULN</p></list-item><list-item id="cts70208-li-0016"><p>T&#8208;bilirubin &gt;&#8201;1.5&#8201;&#215;&#8201;ULN</p></list-item><list-item id="cts70208-li-0017"><p>&#947;&#8208;GTP &gt;&#8201;2.5&#8201;&#215;&#8201;ULN</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">Combination of ALP, t&#8208;bilirubin, and &#947;&#8208;GTP criteria corresponding to CTCAE v5.0 Grade 2 or higher (if baseline is within reference interval)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">Increased ALP, t&#8208;bilirubin, and &#947;&#8208;GTP (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">The following conditions are fulfilled on the same day.
<list list-type="bullet" id="cts70208-list-0010"><list-item id="cts70208-li-0018"><p>ALP &gt;&#8201;5&#8201;&#215;&#8201;ULN</p></list-item><list-item id="cts70208-li-0019"><p>T&#8208;bilirubin &gt;&#8201;3.0&#8201;mg/dL</p></list-item><list-item id="cts70208-li-0020"><p>&#947;&#8208;GTP &gt;&#8201;5&#8201;&#215;&#8201;ULN</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">Combination of ALP, t&#8208;bilirubin, and &#947;&#8208;GTP criteria corresponding to CTCAE v5.0 Grade 3 or higher (if baseline is within reference interval)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="center" rowspan="4" valign="top" colspan="1">Kidney function</td><td align="center" valign="top" rowspan="1" colspan="1">Decreased eGFR (&lt;&#8201;60)</td><td align="center" valign="top" rowspan="1" colspan="1">eGFR &lt;&#8201;60&#8201;mL/min/1.73&#8201;m<sup>2</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">Equivalent to CTCAE v5.0 Grade 2 or higher chronic kidney disease</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">Decreased eGFR (&lt;&#8201;30)</td><td align="center" valign="top" rowspan="1" colspan="1">eGFR &lt;&#8201;30&#8201;mL/min/1.73&#8201;m<sup>2</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">Equivalent to CTCAE v5.0 Grade 3 or higher chronic kidney disease</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">Increased serum creatinine (KDIGO AKI stage 1)</td><td align="center" valign="top" rowspan="1" colspan="1">Any of the following conditions is fulfilled.
<list list-type="bullet" id="cts70208-list-0011"><list-item id="cts70208-li-0021"><p>Serum creatinine &#8805;&#8201;1.5&#8201;&#215;&#8201;baseline</p></list-item><list-item id="cts70208-li-0022"><p>Serum creatinine &#8805;&#8201;0.3&#8201;mg/dL&#8201;+&#8201;baseline</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="cts70208-list-0012"><list-item id="cts70208-li-0023"><p>Equivalent to stage 1 AKI in KDIGO diagnostic criteria<xref rid="cts70208-note-0005" ref-type="table-fn">
<sup>b</sup>
</xref>
</p></list-item><list-item id="cts70208-li-0024"><p>If the baseline value of serum creatinine is missing, the baseline value is calculated assuming an eGFR as 75&#8201;mL/min/1.73&#8201;m<sup>2</sup>.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">Increased serum creatinine (KDIGO AKI stage 3)</td><td align="center" valign="top" rowspan="1" colspan="1">Any of the following conditions is fulfilled.
<list list-type="bullet" id="cts70208-list-0013"><list-item id="cts70208-li-0025"><p>Serum creatinine &#8805;&#8201;3&#8201;&#215;&#8201;baseline</p></list-item><list-item id="cts70208-li-0026"><p>Serum creatinine &#8805;&#8201;4&#8201;mg/dL</p></list-item><list-item id="cts70208-li-0027"><p>eGFR &lt;&#8201;35&#8201;mL/min/1.73&#8201;m<sup>2</sup> and age&#8201;&lt;&#8201;18&#8201;years</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="cts70208-list-0014"><list-item id="cts70208-li-0028"><p>Equivalent to stage 3 AKI in KDIGO diagnostic criteria<xref rid="cts70208-note-0005" ref-type="table-fn">
<sup>b</sup>
</xref>
</p></list-item><list-item id="cts70208-li-0029"><p>If the baseline value of serum creatinine is missing, the baseline value is calculated assuming an eGFR as 75&#8201;mL/min/1.73&#8201;m<sup>2</sup>
</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">18</td><td align="center" rowspan="13" valign="top" colspan="1">Blood</td><td align="center" valign="top" rowspan="1" colspan="1">Leukopenia (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>White blood cell count &lt;&#8201;3000/&#956;L</p>
<p>Hemoglobin &lt;&#8201;10.0&#8201;g/dL</p>
</td><td align="center" rowspan="5" valign="top" colspan="1">Equivalent to CTCAE v5.0 Grade 2 or higher decreased white blood cell count, neutrophil count, lymphocyte count, hemoglobin, or platelet count</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="center" valign="top" rowspan="1" colspan="1">Neutropenia (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">Neutrophil count &lt;&#8201;1500/&#956;L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">Lymphocytopenia (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">Lymphocyte count &lt;&#8201;800/&#956;L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">Anemia (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">Hemoglobin &lt;&#8201;10.0&#8201;g/dL</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">Thrombocytopenia (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">Platelet count &lt;&#8201;75,000/&#956;L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">Leukopenia (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">White blood cell count &lt;&#8201;2000/&#956;L</td><td align="center" rowspan="5" valign="top" colspan="1">Equivalent to CTCAE v5.0 Grade 3 or higher decreased white blood cell count, neutrophil count, lymphocyte count, hemoglobin, or platelet count</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="center" valign="top" rowspan="1" colspan="1">Neutropenia (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">Neutrophil count &lt;&#8201;1000/&#956;L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">Lymphocytopenia (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">Lymphocyte count &lt;&#8201;500/&#956;L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">26</td><td align="center" valign="top" rowspan="1" colspan="1">Anemia (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">Hemoglobin &lt;&#8201;&#8201;8.0&#8201;g/dL</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">Thrombocytopenia (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">Platelet count &lt;&#8201;50,000/&#956;L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">Neutropenia (CTCAE Grade 4)</td><td align="center" valign="top" rowspan="1" colspan="1">Neutrophil count &lt;&#8201;500/&#956;L</td><td align="center" valign="top" rowspan="1" colspan="1">Equivalent to CTCAE v5.0 Grade 4 decrease neutrophil count</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">29</td><td align="center" valign="top" rowspan="1" colspan="1">Eosinophilia</td><td align="center" valign="top" rowspan="1" colspan="1">Eosinophil count &#8805;&#8201;700/&#956;L</td><td align="center" valign="top" rowspan="1" colspan="1">Eosinophilia criteria in the laboratory data book<xref rid="cts70208-note-0006" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">Pancytopenia</td><td align="center" valign="top" rowspan="1" colspan="1">The following conditions are fulfilled on the same day.
<list list-type="bullet" id="cts70208-list-0015"><list-item id="cts70208-li-0030"><p>Neutrophil count &lt;&#8201;1500/&#956;L</p></list-item><list-item id="cts70208-li-0031"><p>Hemoglobin &lt;&#8201;10.0&#8201;g/dL</p></list-item><list-item id="cts70208-li-0032"><p>Platelet count &lt;&#8201;100,000/&#956;L</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">Pancytopenia based on the diagnostic criteria for aplastic anemia in the study group on idiopathic hematopoietic disorders<xref rid="cts70208-note-0007" ref-type="table-fn">
<sup>d</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">31</td><td align="center" rowspan="16" valign="top" colspan="1">Others</td><td align="center" valign="top" rowspan="1" colspan="1">Increased SP&#8208;A</td><td align="center" valign="top" rowspan="1" colspan="1">SP&#8208;A&#8201;&#8805;&#8201;43.8&#8201;ng/mL</td><td align="center" valign="top" rowspan="1" colspan="1">Corresponding to the criteria for elevated SP&#8208;A in the laboratory data book<xref rid="cts70208-note-0006" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">32</td><td align="center" valign="top" rowspan="1" colspan="1">Increased SP&#8208;D</td><td align="center" valign="top" rowspan="1" colspan="1">SP&#8208;D&#8201;&#8805;&#8201;110&#8201;ng/mL</td><td align="center" valign="top" rowspan="1" colspan="1">Corresponding to the criteria for elevated SP&#8208;D in the laboratory data book<xref rid="cts70208-note-0006" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">33</td><td align="center" valign="top" rowspan="1" colspan="1">Increased KL&#8208;6</td><td align="center" valign="top" rowspan="1" colspan="1">KL&#8208;6&#8201;&#8805;&#8201;500&#8201;U/mL</td><td align="center" valign="top" rowspan="1" colspan="1">Corresponds to the criteria for elevated KL&#8208;6 in the laboratory data book<xref rid="cts70208-note-0006" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">Increased SP&#8208;A, SP&#8208;D or KL&#8208;6</td><td align="center" valign="top" rowspan="1" colspan="1">Any of the following conditions is fulfilled.
<list list-type="bullet" id="cts70208-list-0016"><list-item id="cts70208-li-0033"><p>SP&#8208;A&#8201;&#8805;&#8201;43.8&#8201;ng/mL</p></list-item><list-item id="cts70208-li-0034"><p>SP&#8208;D&#8201;&#8805;&#8201;110&#8201;ng/mL</p></list-item><list-item id="cts70208-li-0035"><p>KL&#8208;6&#8201;&#8805;&#8201;500&#8201;U/mL</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">Those falling under any of the outcome nos. 31, 32 or 33</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">Hyponatremia (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">Na&#8201;&#8804;&#8201;129&#8201;mmol/L</td><td align="center" rowspan="6" valign="top" colspan="1">Equivalent to Grade 2 or higher of CTCAE v5.0 (equivalent to Grade 1 or higher for hypokalemia)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">36</td><td align="center" valign="top" rowspan="1" colspan="1">Hypernatremia (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">Na&#8201;&gt;&#8201;150&#8201;mmol/L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">37</td><td align="center" valign="top" rowspan="1" colspan="1">Hypokalemia (CTCAE Grade 1/2)</td><td align="center" valign="top" rowspan="1" colspan="1">K&lt;LLN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">38</td><td align="center" valign="top" rowspan="1" colspan="1">Hyperkalemia (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">K&#8201;&gt;&#8201;5.5&#8201;mmol/L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">39</td><td align="center" valign="top" rowspan="1" colspan="1">Hypocalcemia (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">Ca&#8201;&lt;&#8201;8.0&#8201;mg/dL</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">40</td><td align="center" valign="top" rowspan="1" colspan="1">Hypercalcemia (CTCAE Grade 2)</td><td align="center" valign="top" rowspan="1" colspan="1">Ca&#8201;&gt;&#8201;11.5&#8201;mg/dL</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">41</td><td align="center" valign="top" rowspan="1" colspan="1">Hyponatremia (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">Na&#8201;&#8804;&#8201;124&#8201;mmol/L</td><td align="center" rowspan="6" valign="top" colspan="1">Equivalent to CTCAE v5.0 grade 3 or higher</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">42</td><td align="center" valign="top" rowspan="1" colspan="1">Hypernatremia (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">Na&#8201;&gt;&#8201;155&#8201;mmol/L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">43</td><td align="center" valign="top" rowspan="1" colspan="1">Hypokalemia (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">K&#8201;&lt;&#8201;3.0&#8201;mmol/L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">44</td><td align="center" valign="top" rowspan="1" colspan="1">Hyperkalemia (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">K&#8201;&gt;&#8201;6.0&#8201;mmol/L</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">45</td><td align="center" valign="top" rowspan="1" colspan="1">Hypocalcemia (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">Ca&#8201;&lt;&#8201;7.0&#8201;mg/dL</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">46</td><td align="center" valign="top" rowspan="1" colspan="1">Hypercalcemia (CTCAE Grade 3)</td><td align="center" valign="top" rowspan="1" colspan="1">Ca&#8201;&gt;&#8201;12.5&#8201;mg/dL</td></tr></tbody></table><table-wrap-foot id="cts70208-ntgp-0002"><fn id="cts70208-note-0003"><p>Abbreviations: AKI, acute kidney injury; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, common terminology criteria for adverse events; eGFR, estimated glomerular filtration rate; KDIGO, kidney disease improving global outcomes; KL&#8208;6, sialic carbohydrate antigen KL&#8208;6; LLN lower limit of normal; SP&#8208;A, surfactant protein A; SP&#8208;D, surfactant protein D; t&#8208;bilirubin, total bilirubin; ULN, upper limit of normal; &#947;&#8208;GTP, &#947;&#8208;glutamyltranspeptidase.</p></fn><fn id="cts70208-note-0004"><label>
<sup>a</sup>
</label><p>U.S. Food and Drug Administration. Guidance for Industry Drug&#8208;Induced Liver Injury: Premarketing Clinical Evaluation. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf" ext-link-type="uri">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf</ext-link>.</p></fn><fn id="cts70208-note-0005"><label>
<sup>b</sup>
</label><p>Japanese Society of Nephrology. &#8220;Evidence&#8208;based Clinical Practice Guidelines for CKD 2018&#8221; [in Japanese]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cdn.jsn.or.jp/data/CKD2018.pdf" ext-link-type="uri">https://cdn.jsn.or.jp/data/CKD2018.pdf</ext-link>.</p></fn><fn id="cts70208-note-0006"><label>
<sup>c</sup>
</label><p>Takaku, F. (Supervising Editor), &#8220;Laboratory test data book 2019&#8208;2020&#8221; [in Japanese]. Igaku&#8208;Shoin. 2019.</p></fn><fn id="cts70208-note-0007"><label>
<sup>d</sup>
</label><p>Working group for creating a revised version of the guidelines for the diagnostic criteria and clinical practice for aplastic anemia. &#8220;Guidance for the diagnostic criteria and clinical practice of aplastic anemia&#8221; [in Japanese]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://zoketsushogaihan.umin.jp/file/2022/Aplastic_Anemia.pdf" ext-link-type="uri">http://zoketsushogaihan.umin.jp/file/2022/Aplastic_Anemia.pdf</ext-link>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cts70208-sec-0008"><label>2.3</label><title>Analytical Approaches of the Function</title><p>Table&#160;<xref rid="cts70208-tbl-0002" ref-type="table">2</xref> lists the types of results automatically calculated by the function. These include the number of patients in various categories, demographic data (sex and age), baseline categories of laboratory test results, and various outcomes, including incidence rate in the exposure and control groups and adjusted hazard ratio (aHR) with a 95% confidence interval (CI) by using the Cox proportional hazards model.</p><table-wrap position="float" id="cts70208-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Results available in the new function.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Type</th><th align="center" valign="bottom" rowspan="1" colspan="1">Description</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Patient number</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="order" id="cts70208-list-0017"><list-item id="cts70208-li-0036"><p>Number of patients who met the inclusion criteria</p></list-item><list-item id="cts70208-li-0037"><p>Number of patients who met the inclusion criteria and did not meet the exclusion criteria</p></list-item><list-item id="cts70208-li-0038"><p>Number of patients in the exposed or control group</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Demographic data (sex and age)</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="order" id="cts70208-list-0018"><list-item id="cts70208-li-0039"><p>Number of patients by sex (<italic toggle="yes">n</italic>, %)</p></list-item><list-item id="cts70208-li-0040"><p>Number of patients by age (&lt;&#8201;65 or&#8201;&#8805;&#8201;65&#8201;years) (<italic toggle="yes">n</italic>, %)</p></list-item><list-item id="cts70208-li-0041"><p>Mean age with standard deviation</p></list-item><list-item id="cts70208-li-0042"><p>Median age with first&#8208;third quartiles</p></list-item><list-item id="cts70208-li-0043"><p>Maximum and minimum age</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Baseline categories</p>
<p>(See Table&#160;<xref rid="cts70208-supitem-0001" ref-type="supplementary-material">S1</xref> for more details of categories for each test item)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Number of patients in each baseline category based on baseline values for each laboratory test item (<italic toggle="yes">n</italic>, %) during the researcher&#8208;specified look&#8208;back period (look&#8208;back period 2: from X days before <italic toggle="yes">t</italic>
<sub>0</sub> to <italic toggle="yes">t</italic>
<sub>0</sub>). The baseline value was defined as a value closest to <italic toggle="yes">t</italic>
<sub>0</sub> in case of more than one test results available during the look&#8208;back period 2. The first value was used if multiple values were recorded on the same day.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Status of outcomes (each laboratory test item)</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="order" id="cts70208-list-0019"><list-item id="cts70208-li-0044"><p>Number of outcomes in exposure and control</p></list-item><list-item id="cts70208-li-0045"><p>Incidence rate of outcomes in exposure and control</p></list-item><list-item id="cts70208-li-0046"><p>Incidence proportion of outcomes in exposure and control</p></list-item><list-item id="cts70208-li-0047"><p>Crude hazard ratio with 95% confidence interval of exposure to control estimated by Cox proportional hazards model</p></list-item><list-item id="cts70208-li-0048"><p>Crude risk ratio with 95% confidence interval of exposure to control (assuming the log risk ratio is normally distributed)</p></list-item><list-item id="cts70208-li-0049"><p>Sex and age&#8208;adjusted hazard ratio (aHR) with 95% confidence interval of exposure to control estimated by Cox proportional hazards model</p></list-item><list-item id="cts70208-li-0050"><p>Summary statistics of the follow&#8208;up period (mean with a standard deviation, median with an interquartile range, maximum, and minimum)</p></list-item><list-item id="cts70208-li-0051"><p>Summary statistics of the period to the outcome occurrence (mean with a standard deviation, median with an interquartile range, maximum, and minimum)</p></list-item></list>
</td></tr></tbody></table></table-wrap><p>The outcomes described in Table&#160;<xref rid="cts70208-tbl-0002" ref-type="table">2</xref> were calculated for the entire cohort and subgroups I and II. Subgroup I comprised patients with normal or missing baseline data. In contrast, subgroup II only included patients with normal baseline data (see Table&#160;<xref rid="cts70208-supitem-0001" ref-type="supplementary-material">S1</xref> for more details on the normal function category). Subgroup I was created to provide reference information that supplemented the results in subgroup II, particularly in cases where many missing values on a target laboratory test were expected at baseline. This analysis could be repeated periodically (e.g., every 3&#8201;months) to update the results.</p></sec><sec id="cts70208-sec-0009"><label>2.4</label><title>A Study for Continuous Safety Monitoring of an Anti&#8208;<styled-content style="fixed-case" toggle="no">COVID</styled-content>&#8208;19 Drug</title><p>We examined the practical utility of this new function through a real use case with the following requirements: (1) results on a large number of outcomes (i.e., 46 outcomes) based on laboratory test results can be provided appropriately; (2) study requests can be completed promptly (within 15&#8201;days); and (3) the automated process for analysis can reduce workload. The study for Tix/cil was approved in December 2022 through a discussion by the expert committee of MID&#8208;NET<sup>&#174;</sup> [<xref rid="cts70208-bib-0018" ref-type="bibr">18</xref>]. As this study was conducted as an official activity of the PMDA under the Pharmaceuticals and Medical Devices Agency Law (Articles 15&#8211;5&#8211;[c] and [f]), it was not subject to review by an institutional review board [<xref rid="cts70208-bib-0019" ref-type="bibr">19</xref>, <xref rid="cts70208-bib-0020" ref-type="bibr">20</xref>], and the requirement for obtaining informed consent from the patients was waived. However, the opportunity for a patient to opt out of MID&#8208;NET<sup>&#174;</sup> was ensured by all MID&#8208;NET<sup>&#174;</sup> cooperative hospitals.</p><p>The study period was January 1, 2016 to December 31, 2023; target drugs were tix/cil as the exposure, the combination product of casirivimab and imdevimab (cas/imd) as control&#8208;1, and peramivir as control&#8208;2; look&#8208;back periods 1 and 2 were 90&#8201;days each; start date of the follow&#8208;up period was the day after <italic toggle="yes">t</italic>
<sub>0</sub>; the gap and grace periods were 30&#8201;days each. Regarding the control, cas/imd was selected as control&#8208;1 because its indication is the same as for tix/cil (exposure), with a similar clinical positioning in Japan. However, cas/imd was approved in June 2021, and no safety profile has been established in Japan. Therefore, we considered it appropriate to set peramivir as control&#8208;2 because it was approved in January 2010, has more than a 10&#8208;year marketing history in Japan, and has a relatively well&#8208;established safety profile with more patient data expected to be available for analysis. Whereas the PI of peramivir already included safety warnings on many outcomes related to liver and kidney functions as well as the blood system at the planning stage of this study [<xref rid="cts70208-bib-0021" ref-type="bibr">21</xref>], no safety warnings on the outcomes evaluated in this study were included in the package insert (PI) of cas/imd [<xref rid="cts70208-bib-0022" ref-type="bibr">22</xref>]. Data analysis for all available target outcomes was repeated approximately every 2&#8201;months during the study period.</p></sec></sec><sec sec-type="results" id="cts70208-sec-0010"><label>3</label><title>Results</title><p>Results on all 46 outcomes were provided within the expected timeline of 15&#8201;days throughout the study period. The manual process, which includes developing analytical programs, executing a study, and formatting study results, usually takes a few months for each iteration, even for a simple study protocol. Therefore, we considered the new function to be successful from a time&#8208;saving perspective.</p><p>The actual study results are shown in Figure&#160;<xref rid="cts70208-fig-0002" ref-type="fig">2</xref>, focusing on the outcomes during the latest data period in subgroup II (i.e., population with normal function at baseline), which is usually considered an appropriate population for data interpretation. The number of patients varied according to the outcome, but there were approximately 600&#8211;1000, 50&#8211;100, and 1000&#8211;2000 patients for tix/cil, cas/imd, and peramivir, respectively. Compared with cas/imd, the aHRs for most outcomes, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), eGFR, and neutropenia, were close to or lower than 1.0, with a 95% CI that included 1.0. The aHRs for lymphocytopenia (common terminology criteria for adverse events [CTCAE] Grades 2 and 3), hyponatremia (CTCAE Grade 2), and hypokalemia (CTCAE Grade 2) were significantly lower than 1.0 for tix/cil as compared to those of cas/imd. Contrarily, the aHRs for tix/cil, as compared with peramivir, were significantly higher than 1.0 for thrombocytopenia (CTCAE Grades 2 and 3) and higher for leukopenia (CTCAE Grades 2 and 3), but were significantly lower for increased AST (CTCAE Grade 2), increased ALT (CTCAE Grade 2), increased ALP (CTCAE Grade 2), increased serum creatinine (SCr) (kidney disease improving global outcomes [KDIGO] acute kidney injury [AKI] Stage 1), anemia (CTCAE Grade 2), hyponatremia (CTCAE Grade 2), hypernatremia (CTCAE Grade 2), hypokalemia (CTCAE Grades 2 and 3), and hyperkalemia (CTCAE Grades 2 and 3).</p><fig position="float" fig-type="FIGURE" id="cts70208-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Results of all outcomes in the subgroup II at the latest data period. &#8722;, aHR could not be calculated due to non&#8208;observed cases in either the exposure or control group; aHR, adjusted hazard ratio; AKI, acute kidney injury; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; cas/imd, combination product of casirivimab and imdevimab; CI, confidence interval; CTCAE, common terminology criteria for adverse events; eGFR, estimated glomerular filtration rate; KDIGO, kidney disease improving global outcomes; KL&#8208;6, sialic carbohydrate antigen KL&#8208;6; SCr, serum creatinine; SP&#8208;A, surfactant protein A; SP&#8208;D, surfactant protein D; t&#8208;bilirubin, total bilirubin; tix/cil, combination product of tixagevimab and cilgavimab; &#947;&#8208;GTP, &#947;&#8208;glutamyltranspeptidase. It should be noted that aHR &gt;&#8201;1.0 and aHR &lt;&#8201;1.0 suggest a higher and a lower risk of tix/cil (exposure) in comparison with the control (cas/imd or peramivir), respectively. Numbers in each bracket [] show the number of patients included for analysis of each outcome in exposure (exp) and control (con) groups, respectively. When the patient number was less than 10, the value of &lt;&#8201;10 was presented as an aggregated value based on the MID&#8208;NET<sup>&#174;</sup> publication rule.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CTS-18-e70208-g001.jpg"/></fig><p>When the analysis was repeated with newer data, point estimates of aHRs gradually became stable over the study period, but the 95% CI remained large. Figure&#160;<xref rid="cts70208-fig-0003" ref-type="fig">3</xref> shows the typical patterns observed when the analysis was repeated.</p><fig position="float" fig-type="FIGURE" id="cts70208-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Results in the population with normal baseline ranges of laboratory tests through repeated analysis using the new function. cas/imd, combination product of casirivimab and imdevimab; CTCAE, common terminology criteria for adverse events; tix/cil, combination product of tixagevimab and cilgavimab.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="CTS-18-e70208-g003.jpg"/></fig><p>For example, the aHR for hyperkalemia (CTCAE Grade 2) for tix/cil as compared with cas/imd was higher than 1.0 initially, but it gradually approached 1.0, becoming a stable point estimate in the later period (Figure&#160;<xref rid="cts70208-fig-0003" ref-type="fig">3a</xref>). A similar trend was observed for increased ALT (CTCAE Grade 2) and neutropenia (CTCAE Grade 3) (data not shown). The second pattern was likely the aHR for increased AST or ALT and t&#8208;bilirubin, as compared with that of peramivir, which showed a lower aHR (&lt;&#8201;1.0) at the beginning but gradually reached 1.0 with a stable point estimate in the later period. However, the 95% CI was still large (Figure&#160;<xref rid="cts70208-fig-0003" ref-type="fig">3b</xref>). The trend of aHR for thrombocytopenia (CTCAE Grade 3) compared to peramivir was the third and most important pattern. It showed a higher aHR (&gt;&#8201;1.0) with a large 95% CI at the beginning and continued to maintain a higher aHR (&gt;&#8201;1.0) at the end of the study period. Similarly, the aHR for leukopenia (CTCAE Grades 2 and 3) as compared with peramivir maintained a higher aHR (&gt;&#8201;1.0) in the middle of the study period. However, no significant difference was observed in the later period owing to the large 95% CI (data not shown). It should be noted that aHR could not be calculated for some outcomes, such as increased ALP (CTCAE Grade 3), decreased eGFR (&lt;&#8201;30), increased surfactant protein A (SP&#8208;A), surfactant protein D (SP&#8208;D), and sialic carbohydrate antigen KL&#8208;6 (KL&#8208;6), hypocalcemia, and hypercalcemia because there were no cases in either the exposure or control groups.</p></sec><sec sec-type="discussion" id="cts70208-sec-0011"><label>4</label><title>Discussion</title><p>We developed a new function incorporated in MID&#8208;NET<sup>&#174;</sup> for rapid and continuous monitoring of safety signals with a large number of outcomes. We assessed its practical utility through a safety monitoring study using tix/cil. Some methods for signal detection based on healthcare databases have been reported through a drug safety assessment, including the use of a sequential analysis approach [<xref rid="cts70208-bib-0004" ref-type="bibr">4</xref>, <xref rid="cts70208-bib-0023" ref-type="bibr">23</xref>, <xref rid="cts70208-bib-0024" ref-type="bibr">24</xref>, <xref rid="cts70208-bib-0025" ref-type="bibr">25</xref>, <xref rid="cts70208-bib-0026" ref-type="bibr">26</xref>]. Our new function builds on those of other studies but has made full use of the unique characteristics of MID&#8208;NET<sup>&#174;</sup>. Particularly, this function uses laboratory test results available in a timely manner (within a maximum of 15&#8201;days from the date of study request) to assess multiple health outcomes. The analyses that can be easily repeated for sequential analysis with less human load will advance the routine process of drug safety monitoring based on RWD at the post&#8208;marketing stage in Japan, especially in terms of the efficient and rapid accumulation of scientific evidence.</p><p>The results obtained at the early stage after tix/cil approval facilitated an understanding of the safety profile of this product. Because of small sample sizes, the early&#8208;stage results were usually unstable (i.e., high variation from one time period to the next) for many outcomes, but were nevertheless useful in identifying a potential safety signal as early as possible. The point estimate of aHRs eventually converged to a more stable value by repeating the same analysis with large sample sizes, even if the 95% CI remained large. Another important finding from the study was how results over time varied among the outcomes. This suggests that changes in outcomes over time are important to interpret study results. As reported previously [<xref rid="cts70208-bib-0027" ref-type="bibr">27</xref>], the results from this study support the advantage of a sequential analysis approach for the timely detection of drug safety signals.</p><p>The outcomes with higher aHRs even after a repeated analysis, such as for thrombocytopenia and leukopenia from tix/cil use compared to those from peramivir use, could represent a new safety signal for tix/cil. These risks may be potentially higher in tix/cil than in peramivir, although the risks for tix/cil were not suggested in clinical trial data and information at the time of its approval [<xref rid="cts70208-bib-0017" ref-type="bibr">17</xref>]. A more carefully planned pharmacoepidemiological study may be necessary to clarify or verify the safety signals identified by the new function.</p><p>The results of the outcomes with an aHR near 1.0 (e.g., AST, ALT, and ALP compared with cas/imd) could also be useful for enriching drug safety information with results from clinical practice. In the present case, no safety concerns for tix/cil were suggested in real&#8208;world clinical practice because of the lack of safety warnings in the PI in the control group (cas/imd). These data contribute to a better understanding of the drug safety profiles as early as possible at the post&#8208;marketing stage, even though no safety signals are identified. This could be because real&#8208;world clinical practice differs from the clinical trials before approval (e.g., higher proportion of elderly patients, patients using concomitant medications, and/or patients with comorbidities). This suggests that a sequential analysis approach can also play an essential role beyond safety signal detection in monitoring the real&#8208;world safety of a drug after its approval.</p><p>The aHRs for tix/cil compared to cas/imd for hyponatremia (CTCAE Grade 2) and hypokalemia (CTCAE Grade 2) were consistently &lt;&#8201;1.0, which may indicate a potential safety signal for the control. The lower aHRs for tix/cil as compared with peramivir (e.g., increased AST [CTCAE Grades 2 and 3], increased SCr [KDIGO AKI stage 1], and anemia [CTCAE Grade 2]) may suggest fewer concerns about the safety of tix/cil compared to peramivir. The clinical significance and impact of the results obtained in the new function should be considered. For example, attention should be paid when the aHR is similar to (or higher than) that of a positive control. Contrarily, an aHR that is similar to (or lower than) that of a negative control may indicate that a new drug can be safely used in clinical practice. Therefore, the control used should be carefully selected by considering a drug's clinical positioning and safety characteristics, and a set of two simultaneous control groups with different safety warning statuses should be included in the analysis, as in the real use case described above.</p><p>Additionally, caution is needed when an aHR is not calculated. For example, the lack of cases with more severe outcomes, such as those with CTCAE Grade 3 and eGFR of &lt;&#8201;30, may simply be due to these being rare events in clinical practice. Secondly, not observing outcomes related to specific biomarkers and calcium may indicate these laboratory tests are rarely used in clinical practice. Such outcomes may be identified only when more patient data are accumulated in MID&#8208;NET<sup>&#174;</sup>.</p><p>The result observed in this study would contribute to the systematic assessment of drug safety signals soon after drug approval. Several challenges and limitations were identified in this study. First, expansion beyond the current 46 outcomes available may make this function more useful to detect safety signals. Second, refining the analytical conditions of an automated process would provide better analytical results for interpretation because the current system allows only 2 basic factors (i.e., sex and age) to adjust confounding factors. Applying more rigorous approaches, such as the automatic identification of empirical covariates using a high&#8208;dimensional propensity score, would improve this function [<xref rid="cts70208-bib-0028" ref-type="bibr">28</xref>]. Third, it is necessary to consider the reasonable frequency and total study period for the sequential analysis of the utility of this function as a routine assessment tool of drug safety by the PMDA to strike a balance between scientific accuracy and effort. Using our function for a particular drug, especially for new drugs whose safety profiles are not well established, will provide further suggestions for its improvement to better monitor post&#8208;marketing drug safety. It is expected that the use of this function, along with traditional approaches, including a pharmacoepidemiological study with a manually customized program [<xref rid="cts70208-bib-0006" ref-type="bibr">6</xref>, <xref rid="cts70208-bib-0008" ref-type="bibr">8</xref>, <xref rid="cts70208-bib-0010" ref-type="bibr">10</xref>] and a study based on spontaneous adverse drug reaction reports [<xref rid="cts70208-bib-0029" ref-type="bibr">29</xref>, <xref rid="cts70208-bib-0030" ref-type="bibr">30</xref>], will strengthen the drug safety monitoring system in Japan.</p></sec><sec sec-type="conclusions" id="cts70208-sec-0012"><label>5</label><title>Conclusions</title><p>Our newly developed function can be used to rapidly and continuously monitor drug safety signals on various outcomes at the early post&#8208;marketing stage. It can contribute to strengthening the drug safety monitoring system in Japan. A real use case of an anti&#8208;COVID&#8208;19 drug provided many valuable insights for establishing a best practice for safety signal monitoring using our function. More practical use of this function will provide further suggestions for its improvement to better monitor drug safety in Japan.</p></sec><sec id="cts70208-sec-0013"><title>Author Contributions</title><p>All authors wrote the manuscript; Y.O., T.A., F.T., K.W., K.K., T.H., S.I., Y.K., and Y.U. designed the research; Y.O. and S.W. performed the research and analyzed the data.</p></sec><sec sec-type="COI-statement" id="cts70208-sec-0015"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="cts70208-sec-0016"><title>Past Presentation on This Research</title><p>A portion of this article is included in the official Pharmaceuticals and Medical Devices Agency (PMDA) report, which is available on the PMDA website (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/files/000267391.pdf" ext-link-type="uri">https://www.pmda.go.jp/files/000267391.pdf</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/files/000267390.pdf" ext-link-type="uri">https://www.pmda.go.jp/files/000267390.pdf</ext-link>).</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cts70208-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Tables S1&#8211;S2.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CTS-18-e70208-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="cts70208-sec-0014"><title>Acknowledgments</title><p>We thank all the project members of MID&#8208;NET<sup>&#174;</sup> for their continuous efforts in maintaining the reliability of MID&#8208;NET<sup>&#174;</sup>. We also thank the members of the Offices of Pharmacovigilance I and II of the Pharmaceuticals and Medical Devices Agency for their helpful comments.</p></ack><ref-list content-type="cited-references" id="cts70208-bibl-0001"><title>References</title><ref id="cts70208-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cts70208-cit-0001"><string-name name-style="western"><given-names>C.</given-names><surname>Ishiguro</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Takeuchi</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Uyama</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Tawaragi</surname></string-name>, &#8220;<article-title>The MIHARI Project: Establishing a New Framework for Pharmacoepidemiological Drug Safety Assessments by the Pharmaceuticals and Medical Devices Agency of Japan</article-title>,&#8221; <source>Pharmacoepidemiology and Drug Safety</source><volume>25</volume>, no. <issue>7</issue> (<year>2016</year>): <fpage>854</fpage>&#8211;<lpage>859</lpage>, <pub-id pub-id-type="doi">10.1002/pds.4032</pub-id>.<pub-id pub-id-type="pmid">27222073</pub-id></mixed-citation></ref><ref id="cts70208-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cts70208-cit-0002"><string-name name-style="western"><given-names>C.</given-names><surname>Palleria</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Leporini</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Chimirri</surname></string-name>, et&#160;al., &#8220;<article-title>Limitations and Obstacles of the Spontaneous Adverse Drugs Reactions Reporting: Two &#8220;Challenging&#8221; Case Reports</article-title>,&#8221; <source>Journal of Pharmacology and Pharmacotherapeutics</source><volume>4</volume>, no. <issue>1_suppl</issue> (<year>2013</year>): <fpage>S66</fpage>&#8211;<lpage>S72</lpage>, <pub-id pub-id-type="doi">10.4103/0976-500x.120955</pub-id>.<pub-id pub-id-type="pmid">24347986</pub-id><pub-id pub-id-type="pmcid">PMC3853673</pub-id></mixed-citation></ref><ref id="cts70208-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cts70208-cit-0003"><string-name name-style="western"><given-names>S.</given-names><surname>Matsuda</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Aoki</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kawamata</surname></string-name>, et&#160;al., &#8220;<article-title>Bias in Spontaneous Reporting of Adverse Drug Reactions in Japan</article-title>,&#8221; <source>PLoS One</source><volume>10</volume>, no. <issue>5</issue> (<year>2015</year>): <elocation-id>e0126413</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0126413</pub-id>.<pub-id pub-id-type="pmid">25933226</pub-id><pub-id pub-id-type="pmcid">PMC4416713</pub-id></mixed-citation></ref><ref id="cts70208-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cts70208-cit-0004"><string-name name-style="western"><given-names>A.</given-names><surname>Coste</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Wong</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Bokern</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Bate</surname></string-name>, and <string-name name-style="western"><given-names>I. J.</given-names><surname>Douglas</surname></string-name>, &#8220;<article-title>Methods for Drug Safety Signal Detection Using Routinely Collected Observational Electronic Health Care Data: A Systematic Review</article-title>,&#8221; <source>Pharmacoepidemiology and Drug Safety</source><volume>32</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>28</fpage>&#8211;<lpage>43</lpage>, <pub-id pub-id-type="doi">10.1002/pds.5548</pub-id>.<pub-id pub-id-type="pmid">36218170</pub-id><pub-id pub-id-type="pmcid">PMC10092128</pub-id></mixed-citation></ref><ref id="cts70208-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cts70208-cit-0005"><string-name name-style="western"><given-names>S. E.</given-names><surname>Davis</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zabotka</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Desai</surname></string-name>, et&#160;al., &#8220;<article-title>Use of Electronic Health Record Data for Drug Safety Signal Identification: A Scoping Review</article-title>,&#8221; <source>Drug Safety</source><volume>46</volume>, no. <issue>8</issue> (<year>2023</year>): <fpage>725</fpage>&#8211;<lpage>742</lpage>, <pub-id pub-id-type="doi">10.1007/s40264-023-01325-0</pub-id>.<pub-id pub-id-type="pmid">37340238</pub-id><pub-id pub-id-type="pmcid">PMC11635839</pub-id></mixed-citation></ref><ref id="cts70208-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cts70208-cit-0006"><string-name name-style="western"><given-names>K.</given-names><surname>Kajiyama</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ishiguro</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ando</surname></string-name>, et&#160;al., &#8220;<article-title>Nested Case&#8208;Control Study Utilizing MID&#8208;NET<sup>&#174;</sup> on Thrombocytopenia Associated With Pegfilgrastim in Patients Treated With Antineoplastic Agents</article-title>,&#8221; <source>Clinical Pharmacology &amp; Therapeutics</source><volume>110</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>473</fpage>&#8211;<lpage>479</lpage>, <pub-id pub-id-type="doi">10.1002/cpt.2263</pub-id>.<pub-id pub-id-type="pmid">33866559</pub-id><pub-id pub-id-type="pmcid">PMC8359991</pub-id></mixed-citation></ref><ref id="cts70208-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cts70208-cit-0007"><string-name name-style="western"><given-names>S.</given-names><surname>Sawada</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ando</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hirano</surname></string-name>, et&#160;al., &#8220;<article-title>Effect of Hepatitis C Drugs on Blood Coagulability in Patients on Warfarin Using the Medical Information Database Network (MID&#8208;NET<sup>&#174;</sup>) in Japan</article-title>,&#8221; <source>Therapeutic Innovation &amp; Regulatory Science</source><volume>55</volume>, no. <issue>3</issue> (<year>2021</year>): <fpage>539</fpage>&#8211;<lpage>544</lpage>, <pub-id pub-id-type="doi">10.1007/s43441-020-00247-8</pub-id>.<pub-id pub-id-type="pmid">33393016</pub-id><pub-id pub-id-type="pmcid">PMC8021533</pub-id></mixed-citation></ref><ref id="cts70208-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cts70208-cit-0008"><string-name name-style="western"><given-names>T.</given-names><surname>Hasegawa</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sawada</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ishiguro</surname></string-name>, et&#160;al., &#8220;<article-title>Assessing the Risk of Decrease in Kidney Function in Patients Prescribed Direct&#8208;Acting Antivirals for Hepatitis C Utilizing the MID&#8208;NET<sup>&#174;</sup> Medical Information Database Network in Japan</article-title>,&#8221; <source>Therapeutic Innovation &amp; Regulatory Science</source><volume>56</volume>, no. <issue>4</issue> (<year>2022</year>): <fpage>625</fpage>&#8211;<lpage>631</lpage>, <pub-id pub-id-type="doi">10.1007/s43441-022-00400-5</pub-id>.<pub-id pub-id-type="pmid">35437631</pub-id><pub-id pub-id-type="pmcid">PMC9135840</pub-id></mixed-citation></ref><ref id="cts70208-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cts70208-cit-0009"><string-name name-style="western"><given-names>Y.</given-names><surname>Kinoshita</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Kajiyama</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ishiguro</surname></string-name>, et&#160;al., &#8220;<article-title>Characterizing Granulocytopenia Associated With Thiamazole in Patients With Hyperthyroidism Based on Real&#8208;World Data From the MID&#8208;NET<sup>&#174;</sup> in Japan</article-title>,&#8221; <source>Clinical Pharmacology &amp; Therapeutics</source><volume>113</volume>, no. <issue>4</issue> (<year>2023</year>): <fpage>924</fpage>&#8211;<lpage>931</lpage>, <pub-id pub-id-type="doi">10.1002/cpt.2850</pub-id>.<pub-id pub-id-type="pmid">36648197</pub-id></mixed-citation></ref><ref id="cts70208-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cts70208-cit-0010"><string-name name-style="western"><given-names>T.</given-names><surname>Hasegawa</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sawada</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Saito</surname></string-name>, et&#160;al., &#8220;<article-title>Lower Risks of Gastrointestinal Perforation and Intestinal Obstruction in Patients With Atypical Antipsychotics in Comparison With Typical Antipsychotics Based on Real&#8208;World Data From the MID&#8208;NET<sup>&#174;</sup> in Japan</article-title>,&#8221; <source>Therapeutic Innovation &amp; Regulatory Science</source><volume>58</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>192</fpage>&#8211;<lpage>199</lpage>, <pub-id pub-id-type="doi">10.1007/s43441-023-00586-2</pub-id>.<pub-id pub-id-type="pmid">37899426</pub-id><pub-id pub-id-type="pmcid">PMC10764367</pub-id></mixed-citation></ref><ref id="cts70208-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cts70208-cit-0011"><string-name name-style="western"><given-names>H.</given-names><surname>Shida</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Komamine</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Kajiyama</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Waki</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Maruyama</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Uyama</surname></string-name>, &#8220;<article-title>Real&#8208;World Prescription of Anti&#8208;COVID&#8208;19 Drugs in Hospitalized Patients With COVID&#8208;19 in Japan</article-title>,&#8221; <source>PLoS One</source><volume>19</volume>, no. <issue>1</issue> (<year>2024</year>): <elocation-id>e0297679</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0297679</pub-id>.<pub-id pub-id-type="pmid">38277429</pub-id><pub-id pub-id-type="pmcid">PMC10817178</pub-id></mixed-citation></ref><ref id="cts70208-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cts70208-cit-0012"><string-name name-style="western"><given-names>T.</given-names><surname>Waki</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Okada</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Kinoshita</surname></string-name>, et&#160;al., &#8220;<article-title>Prescription Trend and Lactic Acidosis in Patients Prescribed Metformin Before and After the Revision of Package Insert for Allowing Metformin Administration to Patients With Moderately Decreased Kidney Function Based on Real&#8208;World Data From MID&#8208;NET<sup>&#174;</sup> in Japan</article-title>,&#8221; <source>Frontiers in Medicine</source><volume>10</volume> (<year>2024</year>): <elocation-id>1294696</elocation-id>, <pub-id pub-id-type="doi">10.3389/fmed.2023.1294696</pub-id>.<pub-id pub-id-type="pmid">38327270</pub-id><pub-id pub-id-type="pmcid">PMC10847222</pub-id></mixed-citation></ref><ref id="cts70208-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cts70208-cit-0013"><string-name name-style="western"><given-names>M.</given-names><surname>Yamaguchi</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Inomata</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Harada</surname></string-name>, et&#160;al., &#8220;<article-title>Establishment of the MID&#8208;NET<sup>&#174;</sup> Medical Information Database Network as a Reliable and Valuable Database for Drug Safety Assessments in Japan</article-title>,&#8221; <source>Pharmacoepidemiology and Drug Safety</source><volume>28</volume>, no. <issue>10</issue> (<year>2019</year>): <fpage>1395</fpage>&#8211;<lpage>1404</lpage>, <pub-id pub-id-type="doi">10.1002/pds.4879</pub-id>.<pub-id pub-id-type="pmid">31464008</pub-id><pub-id pub-id-type="pmcid">PMC6851601</pub-id></mixed-citation></ref><ref id="cts70208-bib-0014"><label>14</label><mixed-citation publication-type="miscellaneous" id="cts70208-cit-0014"><collab collab-type="authors">Pharmaceuticals and Medical Devices Agency</collab>
, <article-title>&#8220;The Web Page of MID&#8208;NET<sup>&#174;</sup>,&#8221;</article-title> (<year>2024</year>), accessed October 10, 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/safety/mid-net/0001.html" ext-link-type="uri">https://www.pmda.go.jp/safety/mid&#8208;net/0001.html</ext-link>.</mixed-citation></ref><ref id="cts70208-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cts70208-cit-0015"><string-name name-style="western"><given-names>K.</given-names><surname>Yamada</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Itoh</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Fujimura</surname></string-name>, et&#160;al., &#8220;<article-title>The Utilization and Challenges of Japan's MID&#8208;NET<sup>&#174;</sup> Medical Information Database Network in Postmarketing Drug Safety Assessments: A Summary of Pilot Pharmacoepidemiological Studies</article-title>,&#8221; <source>Pharmacoepidemiology and Drug Safety</source><volume>28</volume>, no. <issue>5</issue> (<year>2019</year>): <fpage>601</fpage>&#8211;<lpage>608</lpage>, <pub-id pub-id-type="doi">10.1002/pds.4777</pub-id>.<pub-id pub-id-type="pmid">30945387</pub-id></mixed-citation></ref><ref id="cts70208-bib-0016"><label>16</label><mixed-citation publication-type="miscellaneous" id="cts70208-cit-0016"><collab collab-type="authors">Pharmaceuticals and Medical Devices Agency</collab>
, <article-title>&#8220;The New System for Early Detection of Safety Signal Based on RWD From MID&#8208;NET<sup>&#174;</sup>,&#8221;</article-title> (<year>2024</year>), accessed October 10, 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/safety/surveillance-analysis/0049.html" ext-link-type="uri">https://www.pmda.go.jp/safety/surveillance&#8208;analysis/0049.html</ext-link>.</mixed-citation></ref><ref id="cts70208-bib-0017"><label>17</label><mixed-citation publication-type="miscellaneous" id="cts70208-cit-0017"><collab collab-type="authors">Pharmaceuticals and Medical Devices Agency</collab>
, <article-title>&#8220;The Review Report for Evusheld Intramuscular Injection Set,&#8221;</article-title> (<year>2022</year>), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/files/000250093.pdf" ext-link-type="uri">https://www.pmda.go.jp/files/000250093.pdf</ext-link>.</mixed-citation></ref><ref id="cts70208-bib-0018"><label>18</label><mixed-citation publication-type="miscellaneous" id="cts70208-cit-0018"><collab collab-type="authors">Pharmaceuticals and Medical Devices Agency</collab>
, <article-title>&#8220;Information for Studies Approved Through a Discussion by the Expert Committee of MID&#8208;NET<sup>&#174;</sup> [in Japanese],&#8221;</article-title> (<year>2024</year>), accessed October 10, 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/safety/mid-net/0010.html" ext-link-type="uri">https://www.pmda.go.jp/safety/mid&#8208;net/0010.html</ext-link>.</mixed-citation></ref><ref id="cts70208-bib-0019"><label>19</label><mixed-citation publication-type="miscellaneous" id="cts70208-cit-0019"><collab collab-type="authors">Pharmaceuticals and Medical Devices Agency</collab>
, <article-title>&#8220;Act on the Pharmaceuticals and Medical Devices Agency,&#8221;</article-title> (<year>2024</year>), (Act No.192 of 2002) [in Japanese], accessed Otober 10, 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://elaws.e-gov.go.jp/document?lawid=414AC0000000192" ext-link-type="uri">https://elaws.e&#8208;gov.go.jp/document?lawid=414AC0000000192</ext-link>.</mixed-citation></ref><ref id="cts70208-bib-0020"><label>20</label><mixed-citation publication-type="miscellaneous" id="cts70208-cit-0020"><collab collab-type="authors">Pharmaceuticals and Medical Devices Agency</collab>
, <article-title>&#8220;Pharmacoepidemiological Studies for Drug Safety Assessment Under MIHARI Framework [in Japanese],&#8221;</article-title> (<year>2024</year>), accessed October 10, 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/safety/surveillance-analysis/0045.html" ext-link-type="uri">https://www.pmda.go.jp/safety/surveillance&#8208;analysis/0045.html</ext-link>.</mixed-citation></ref><ref id="cts70208-bib-0021"><label>21</label><mixed-citation publication-type="miscellaneous" id="cts70208-cit-0021"><collab collab-type="authors">Pharmaceuticals and Medical Devices Agency</collab>
, <article-title>&#8220;The Package Insert for RAPIACTA (Peramivir Hydrate) (as of March 2024),&#8221;</article-title> (<year>2024</year>), accessed October 10 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/340018_6250405A1032_1_14" ext-link-type="uri">https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/340018_6250405A1032_1_14</ext-link>.</mixed-citation></ref><ref id="cts70208-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="cts70208-cit-0022"><collab collab-type="authors">Pharmaceuticals and Medical Devices Agency</collab>
, <article-title>&#8220;The Packge Insert for RONAPREVE (Combination Product of Casirivimab and Imdevimab) (as of March 2024),&#8221;</article-title> (<year>2024</year>), accessed October 10, 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/450045_62505A0A1031_1_05" ext-link-type="uri">https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/450045_62505A0A1031_1_05</ext-link>.</mixed-citation></ref><ref id="cts70208-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cts70208-cit-0023"><string-name name-style="western"><given-names>J. J.</given-names><surname>Gagne</surname></string-name>, <string-name name-style="western"><given-names>S. V.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Rassen</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Schneeweiss</surname></string-name>, &#8220;<article-title>A Modular, Prospective, Semi&#8208;Automated Drug Safety Monitoring System for Use in a Distributed Data Environment</article-title>,&#8221; <source>Pharmacoepidemiology and Drug Safety</source><volume>23</volume>, no. <issue>6</issue> (<year>2014</year>): <fpage>619</fpage>&#8211;<lpage>627</lpage>, <pub-id pub-id-type="doi">10.1002/pds.3616</pub-id>.<pub-id pub-id-type="pmid">24788694</pub-id><pub-id pub-id-type="pmcid">PMC4159708</pub-id></mixed-citation></ref><ref id="cts70208-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cts70208-cit-0024"><string-name name-style="western"><given-names>S. K.</given-names><surname>Greene</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Kulldorff</surname></string-name>, <string-name name-style="western"><given-names>E. M.</given-names><surname>Lewis</surname></string-name>, et&#160;al., &#8220;<article-title>Near Real&#8208;Time Surveillance for Influenza Vaccine Safety: Proof&#8208;Of&#8208;Concept in the Vaccine Safety Datalink Project</article-title>,&#8221; <source>American Journal of Epidemiology</source><volume>171</volume>, no. <issue>2</issue> (<year>2010</year>): <fpage>177</fpage>&#8211;<lpage>188</lpage>, <pub-id pub-id-type="doi">10.1093/aje/kwp345</pub-id>.<pub-id pub-id-type="pmid">19965887</pub-id><pub-id pub-id-type="pmcid">PMC2878099</pub-id></mixed-citation></ref><ref id="cts70208-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cts70208-cit-0025"><string-name name-style="western"><given-names>J. J.</given-names><surname>Gagne</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Rassen</surname></string-name>, <string-name name-style="western"><given-names>N. K.</given-names><surname>Choudhry</surname></string-name>, et&#160;al., &#8220;<article-title>Near&#8208;Real&#8208;Time Monitoring of New Drugs: An Application Comparing Prasugrel Versus Clopidogrel</article-title>,&#8221; <source>Drug Safety</source><volume>37</volume>, no. <issue>3</issue> (<year>2014</year>): <fpage>151</fpage>&#8211;<lpage>161</lpage>, <pub-id pub-id-type="doi">10.1007/s40264-014-0136-0</pub-id>.<pub-id pub-id-type="pmid">24510605</pub-id></mixed-citation></ref><ref id="cts70208-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cts70208-cit-0026"><string-name name-style="western"><given-names>F.</given-names><surname>Mayer</surname></string-name>, <string-name name-style="western"><given-names>U.</given-names><surname>Kirchmayer</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Coletta</surname></string-name>, et&#160;al., &#8220;<article-title>Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near&#8208;Real&#8208;Time Monitoring Program in Italy</article-title>,&#8221; <source>Journal of the American Heart Association</source><volume>7</volume>, no. <issue>6</issue> (<year>2018</year>): <elocation-id>e008034</elocation-id>, <pub-id pub-id-type="doi">10.1161/jaha.117.008034</pub-id>.<pub-id pub-id-type="pmid">29525786</pub-id><pub-id pub-id-type="pmcid">PMC5907561</pub-id></mixed-citation></ref><ref id="cts70208-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cts70208-cit-0027"><string-name name-style="western"><given-names>J. S.</given-names><surname>Brown</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Kulldorff</surname></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Chan</surname></string-name>, et&#160;al., &#8220;<article-title>Early Detection of Adverse Drug Events Within Population&#8208;Based Health Networks: Application of Sequential Testing Methods</article-title>,&#8221; <source>Pharmacoepidemiology and Drug Safety</source><volume>16</volume>, no. <issue>12</issue> (<year>2007</year>): <fpage>1275</fpage>&#8211;<lpage>1284</lpage>, <pub-id pub-id-type="doi">10.1002/pds.1509</pub-id>.<pub-id pub-id-type="pmid">17955500</pub-id></mixed-citation></ref><ref id="cts70208-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cts70208-cit-0028"><string-name name-style="western"><given-names>S.</given-names><surname>Schneeweiss</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Rassen</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Glynn</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Avorn</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Mogun</surname></string-name>, and <string-name name-style="western"><given-names>M. A.</given-names><surname>Brookhart</surname></string-name>, &#8220;<article-title>High&#8208;Dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data</article-title>,&#8221; <source>Epidemiology</source><volume>20</volume> (<year>2009</year>): <fpage>512</fpage>&#8211;<lpage>522</lpage>, <pub-id pub-id-type="doi">10.1097/EDE.0b013e3181a663cc29</pub-id>.<pub-id pub-id-type="pmid">19487948</pub-id><pub-id pub-id-type="pmcid">PMC3077219</pub-id></mixed-citation></ref><ref id="cts70208-bib-0029"><label>29</label><mixed-citation publication-type="miscellaneous" id="cts70208-cit-0029"><collab collab-type="authors">Pharmaceuticals and Medical Devices Agency</collab>
, <article-title>&#8220;Information for Spontaneous Case Reports Suspected as Adverse Drug Reaction In Japan [in Japanese],&#8221;</article-title> (<year>2024</year>), accessed October 10, 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/safety/info-services/drugs/adr-info/suspected-adr/0005.html%3e" ext-link-type="uri">https://www.pmda.go.jp/safety/info&#8208;services/drugs/adr&#8208;info/suspected&#8208;adr/0005.html</ext-link>.</mixed-citation></ref><ref id="cts70208-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cts70208-cit-0030"><string-name name-style="western"><given-names>M.</given-names><surname>Fujiwara</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Kawasaki</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Yamada</surname></string-name>, &#8220;<article-title>A Pharmacovigilance Approach for Post&#8208;Marketing in Japan Using the Japanese Adverse Drug Event Report (JADER) Database and Association Analysis</article-title>,&#8221; <source>PLoS One</source><volume>11</volume>, no. <issue>4</issue> (<year>2016</year>): <elocation-id>e0154425</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0154425</pub-id>.<pub-id pub-id-type="pmid">27119382</pub-id><pub-id pub-id-type="pmcid">PMC4847915</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>